Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy☆
Y. Zhu, I. Leddin, M. S. Miralles, C. H. Bartlett, N. Turner
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy☆'. Together they form a unique fingerprint.